Rubicon Research Q1 profit up 96% to ₹848 crore; acquires US plant
Rubicon Research delivered strong Q1FY27 results with net profit rising 96% YoY to ₹848 million and revenue growing 51% to ₹5.3 billion. The company expanded its EBITDA margin to 24.15% and revised full-year guidance upwards to 23%. Key strategic moves include the acquisition of a US manufacturing facility for USD2.9 million and successful resolution of FDA observations at its Pithampur plant.
*this image is generated using AI for illustrative purposes only.
Rubicon Research reported a substantial rise in profitability for the first quarter of FY27, with net profit jumping 96% year-on-year to ₹848 million. This compares to a net profit of ₹433 million in the corresponding period of the previous fiscal year. The company’s top-line growth was equally robust, with revenue increasing by 51% to ₹5.3 billion from ₹3.5 billion in the prior year’s first quarter.
The surge in revenue was accompanied by an expansion in operating margins, signaling improved cost management or higher-value mix in its services. During the earnings call held on August 14, 2026, management highlighted that the strong performance included the consolidation of Arinna Lifesciences, which contributed approximately INR12 crores to revenue with no material impact on EBITDA.
Financial Performance Highlights
EBITDA rose to ₹1.29 billion from ₹791 million year-on-year, representing a growth of approximately 63%. More notably, the EBITDA margin expanded by 172 basis points to 24.15%, up from 22.43% in the same quarter last year. Pre-R&D EBITDA margin stood at 35%, up from 32.5% in the prior year. R&D expenses were recorded at INR580 million, translating to 10.9% of revenue.
| Metric: | Q1 Current | Q1 Prior Year | Change |
|---|---|---|---|
| Revenue: | ₹5.3 billion | ₹3.5 billion | +51% |
| EBITDA: | ₹1.29 billion | ₹791 million | +63% |
| EBITDA Margin: | 24.15% | 22.43% | +172 bps |
| Net Profit: | ₹848 million | ₹433 million | +96% |
| Gross Margin: | 67.7% | N/A | N/A |
Strategic Updates and Guidance
Management provided several strategic updates during the conference call. The company revised its full-year FY27 EBITDA margin guidance upwards from an earlier range of 22-23% to a comfortable 23%, despite expected cost impacts from new ESOP schemes, Arinna integration, and pre-revenue costs for new facilities.
Key developments include:
- US Expansion: Rubicon acquired a manufacturing site in East Brunswick, New Jersey, via a court-supervised bankruptcy process for USD2.9 million. The facility, which shares a wall with the company’s distribution operations, is expected to begin commercialization in calendar year 2027. It aims to serve specialty products and US government departments requiring onshore manufacturing.
- Pithampur Facility: The FDA issued Form 483 with two procedural observations during an unannounced inspection in July. Management filed appropriate responses and received FDA approval on a regulatory filing post-inspection. Commercial operations are on track to ramp up from the first quarter of calendar year 2027.
- Leadership Changes: Nitin Jajodia transitions from CFO to Chief Commercial Officer. Rohit will join as CFO designate before moving into the CFO role upon Nitin’s transition.
Operational Efficiency and Cash Flow
Gross margin increased sequentially by around 140 bps to 67.7%, despite rising input and freight costs due to geopolitical conditions. This improvement followed tactical measures taken in previous quarters to reduce reliance on lower-margin contract manufacturing. USD revenues for Q1 were USD55 million, up 32% year-on-year from USD42 million, though there was a slight sequential drop due to these tactical mix changes.
Operating cash flow before working capital change was INR1,390 million, while cash flow from operating activities stood at INR285 million. Management noted that this figure was impacted by delays in GST refunds, which are expected to normalize in Q2. Net working capital days improved to 114 days as on June 30, 2026, from 126 days as on March 31, 2026, though management cautioned against reading too much into quarterly fluctuations.
What the Numbers Show
The divergence between revenue growth (51%) and net profit growth (96%) indicates a leverage effect where fixed costs are being spread over a larger revenue base, or variable costs have decreased as a percentage of sales. The simultaneous expansion in EBITDA margin confirms that the profit growth is operationally driven rather than resulting from one-time gains or tax benefits. The company appears to be scaling efficiently, converting incremental revenue into disproportionately higher bottom-line earnings. Additionally, the strategic shift away from lower-margin outsourced manufacturing towards in-house production is beginning to yield margin improvements, as evidenced by the sequential gross margin expansion.
Existing Snippets: []
Historical Stock Returns for Rubicon Research
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.84% | +8.08% | +18.33% | +125.17% | +184.77% | +184.77% |
How will the consolidation of Arinna Lifesciences impact Rubicon's long-term R&D pipeline and future revenue diversification beyond the initial INR12 crore contribution?
What specific operational challenges or regulatory hurdles might delay the commercialization of the new East Brunswick manufacturing facility in 2027, and how could this affect US government contract acquisition?
Given the recent FDA Form 483 observations at the Pithampur facility, what corrective action plans are in place to ensure smooth commercial ramp-up in early 2027 without further regulatory setbacks?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
